ClinicalTrials.gg
CompletedNCT06971198Updated May 14, 2025

Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HSK39004 Dry Powder Inhalation

A Phase 1 interventional study of HSK39004 and Placebo in Healthy Volunteers, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-14.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

To evaluate the safety, tolerability and pharmacokinetic characteristics of HSK39004 dry powder inhalation in healthy subjects.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Haisco Pharmaceutical Group Co., Ltd. is the lead sponsor of 118 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign the form, understand the trialprocedures, and be willing to comply with all trial procedures andrestrictions;
  2. 18 years to 45 years (inclusive), male and female;
  3. Male subjects weight ≥50 kg and female subjects weight ≥45 kg. (BMI) : 18-26 kg/m2 (inclusive) ;
  4. Normal lung function during the screening period, no airway obstruction, and forced vital capacity(FVC) are at least 80% of the predicted values;
  5. Never smoked or have quit smoking for ≥ 12 months and have a previous smoking history of \< 5 pack per years;
  6. Subjects are willing to voluntarily use effectivecontraceptives from screening to at least 3 months after the last dose administration.

Exclusion criteria

Exclusion Criteria:

  1. Have a history of severe and uncontrolled diseases, such ascardiovascular, respiratory, liver, gastrointestinal, endocrine,hematologic, mental/nervous systems diseases within 3 months prior to screening;
  2. Have a history of any malignant tumors;
  3. Normal or abnormal vital signs, physical examination, laboratory examination, , and imageological examination have no clinical significance;
  4. Previous or current gastrointestinal, liver, kidney, or other disease known to interfere with drug absorption, distribution, metabolism, or excretion;
  5. Acute respiratory infections occurred within 6 weeks before screening and/or before randomization;
  6. Have a history of high consumption of grapefruit juice, methylxanthinerich food or beverage within 48 hours before the administration;
  7. Average alcohol intake is more than 14 unit per week (1unit=10g alcohol , 1 unit=285 mL 4.9% alcohol beer, or 30 mL 40% alcohol spirit, or 100mL 12% alcohol wine) within the 3 months prior to screening;
  8. Have a history of drug abuse prior to screening, or positive urine drug screen at screening;
  9. Blood donation (or blood loss) ≥400 mL within 3 months prior to the screening;
  10. Subjects who have a allergic to any component of HSK39004 or allergic history;
  11. Subjects who use any within 30 days prior to screening;
  12. Have participated in any clinical investigator within 3 months prior to screening;
  13. A pregnant/lactating woman, or has a positive pregnancy test at screening or during the trial;
  14. Not suitable for this study as judged by the investigator.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    HSK39004

    Drug: HSK39004

  • Placebo comparator
    Placebo

    Placebo group

    Drug: Placebo

Interventions

  • 0.75\~4mg

  • DrugPlacebo

    0.75\~4mg

06

What researchers measure

Primary outcomes

  1. adverse events

    Time frame: From the enrollment of the subjects to 72 hours after the last administration

Secondary outcomes

  1. AUC

    area under the concentration-time curve

    Time frame: from 0 to 72 hours after administration

  2. Cmax

    maximum plasma concentration

    Time frame: from 0 to 72 hours after administration

  3. t1/2

    half-life

    Time frame: from 0 to 72 hours after administration

  4. Vz/F

    apparent volume of distribution

    Time frame: from 0 to 72 hours after administration

  5. CL/F

    apparent clearance

    Time frame: from 0 to 72 hours after administration

07

Study locations

1 site
  • Shandong Provincial Qianfoshan Hospital
    Jinan, Shandong, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2025 to primary completion in Mar 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2025
First posted
May 14, 2025
StartActual
Feb 10, 2025
Primary completionActual
Mar 28, 2025
CompletionActual
May 6, 2025
Last update
May 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06971198
Responsible party
Sponsor
First posted
May 14, 2025
Start date
Feb 10, 2025
Primary completion
Mar 28, 2025
Completion
May 6, 2025
Last update
May 14, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HSK39004

Start the discussion